SEC Filings Reveal GlaxoSmithKline's 13% Stake in This Massachusetts Biotech Post author:Sam Post published:November 16, 2017 Post category:BioPharma A filing with the SEC indicates that Glaxo now has a 13 percent stake in Spero Therapeutics. Source: BioSpace You Might Also Like Iovance Biotherapeutics Appoints As Chief Financial Officer August 8, 2017 Minerva Neurosciences Reports First Quarter 2017 Financial Results And Business Updates May 3, 2017 Repros Therapeutics Reports Fourth Quarter And Year End 2016 Financial Results March 30, 2017